c-Met Antibody Drug Conjugates for Targeted NSCLC Cell Killing

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

There is a need for antibody drug conjugates (ADCs) that can effectively target and treat non-small cell lung cancer (NSCLC), as no such treatments have been approved, and aberrant c-Met signaling is common in this type of cancer, leading to poor prognosis and resistance to chemotherapy and radiotherapy.

Innovation Solution

Development of anti-c-Met antibody drug conjugates (ADCs) that specifically bind to human c-Met, utilizing topoisomerase I inhibitors (TOP1i) conjugated to anti-c-Met antibodies via linkers, allowing targeted delivery to tumor cells, thereby enhancing therapeutic efficacy.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional chemotherapy and radiotherapy are used to treat NSCLC, then tumor cells may be killed, but tumor cells develop resistance and prognosis remains poor

Engineering Contradiction:

Improvetherapeutic efficacyVSAvoidresistance to chemotherapy/radiotherapy

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent segments the therapeutic approach by using an antibody component to specifically target c-Met positive tumor cells and a cytotoxic drug component to kill the targeted cells. This segmentation allows selective delivery of the cytotoxic agent only to tumor cells expressing c-Met, avoiding resistance development in non-targeted cells and reducing off-target effects.

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The patent introduces an antibody-cytotoxic conjugate as an intermediary that bridges the targeting function (antibody binding to c-Met) and the therapeutic function (cytotoxic killing). This intermediary structure enables selective delivery of the cytotoxic drug to c-Met positive tumor cells, overcoming resistance to conventional chemotherapy and radiotherapy through targeted mechanism.

Inventive Principle:

Principle #24Intermediary (Mediator)

2Reliability

If antibody drug conjugates are developed to target c-Met, then therapeutic efficacy against NSCLC is improved, but no such conjugates have been approved yet indicating development challenges

Engineering Contradiction:

Improvetherapeutic efficacyVSAvoidADC development complexity

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent merges the antibody component (providing targeting specificity) and the cytotoxic drug component (providing killing efficacy) into a single conjugate molecule. This merging creates a unified therapeutic agent that combines the advantages of both components, achieving improved therapeutic efficacy while addressing the complexity of separate targeted therapy and chemotherapy administration.

Inventive Principle:

Principle #5Merging (Combining)

3Reliability

If cytotoxic drugs are delivered systemically to treat cancer, then tumor cells may be killed, but healthy cells are also damaged causing side effects

Engineering Contradiction:

Improvetumor cell killingVSAvoiddamage to healthy cells

Core Design Contradiction:

ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The patent applies local quality by concentrating the cytotoxic drug effect specifically at the location of c-Met positive tumor cells through antibody-mediated targeting. The antibody component directs the cytotoxic agent to the precise location of tumor cells expressing the target antigen, ensuring that healthy cells are not exposed to the cytotoxic effect and thus avoiding damage to healthy tissues.

Inventive Principle:

Principle #3Local quality

Data Source

PatentUS20260022128A1Anti-c-met antibody drug conjugates

Publication Date: 2026.01.22 ABBVIE MFG MANAGEMENT UNLIMITED CO

AI summary

The present disclosure provides c-Met antibody drug conjugates (ADCs), including compositions and methods of using such ADCs.